Abstract:Background: Restless legs syndrome (RLS) is a distressing and common neurological disorder that may have a huge impact in the quality of life of those with frequent and intense symptoms. Patients complain of unpleasant sensations in the legs, at or before bedtime, and feel an urge to move the legs, which improves with movement, such as walking. Symptoms start with the patient at rest (e.g. sitting or lying down), and follow a circadian pattern, increasing during the evening or at night. Many pharmacological intervention are available for RLS, including drugs used to treat Parkinson's disease (L-Dopa and dopaminergic agonists), epilepsy (anticonvulsants), anxiety (benzodiazepines), and pain (opioids). Dopaminergic drugs are those most frequently used for treatment of RLS, but some patients do not respond effectively and require other medication. Opioids, a class of medications used to treat severe pain, seem to be effective in treating RLS symptoms, and are recommended for patients with severe symptoms, because RLS and pain appear to share the same mechanism in the central nervous system. All available drugs are associated to some degree with side effects, which can impede treatment. Opioids are associated with adverse events such as constipation, tolerance, and dependence. This justifies the conduct of a systematic review to ascertain whether opioids are safe and effective for treatment of RLS. Objectives: To asses the effects of opioids compared to placebo treatment for restless legs syndrome in adults. Search methods: We searched the Cochrane Central Register of Controlled trials, CENTRAL 2016, issue 4 and MEDLINE, EMBASE, and LILACS up to April 2016, using a search strategy adapted by Cochraneto identify randomised clinical trials. We checked the references of each study and established personal communication with other authors to identify any additional studies. We considered publications in all languages. Selection criteria: Randomised controlled clinical trials of opioid treatment in adults with idiopathic RLS. Data collection and analysis: Two review authors independently screened articles, independently extracted data into a standard form, and assessed for risk of bias. If necessary, they discussed discrepancies with a third researcher to resolve any doubts. Main results: We included one randomised clinical trial (N = 304 randomised; 204 completed; 276 analysed) that evaluated opioids (prolonged release oxycodone/naloxone) versus placebo. After 12 weeks, RSL symptoms had improved more in the drug group than in the placebo group (using the IRLSSS: MD -7.0; 95% CI -9.69 to -4.31 and the CGI: MD -1.11; 95% CI -1.49 to -0.73). More patients in the drug group than in the placebo group were drug responders (using the IRLSSS: RR 1.82; 95% CI 1.37 to 2.42 and the CGI: RR1.92; 95% ICI 1.49 to 2.48). The proportion of remitters was greater in the drug group than in the placebo group (using the IRLSSS: RR 2.14; 95% CI 1.45 to 3.16). Quality of life scores also improved more in the drug group than in the placebo group (MD -0.73; 95% CI -1.1 to -0.36). Quality of sleep was improved more in the drug group measured by sleep adequacy (MD -0.74; 95% CI -1.15 to -0.33), and sleep quantity (MD 0.89; 95% CI 0.52 to 1.26).There was no difference between groups for daytime somnolence, trouble staying awake during the day, or naps during the day. More adverse events were reported in the drug group (RR 1.22; 95% CI 1.07 to 1.39). The major adverse events were gastrointestinal problems, fatigue, and headache. Authors' conclusions: Opioids seem to be effective for treating RLS symptoms, but there are no definitive data regarding the important problem of safety. This conclusion is based on only one study with a high dropout rate (moderate quality evidence).

1161 From Restless to Rest – the Use of Methadone to Treat Complex RLS in Patients with Sleep Apnea: A Case Series

1210 Initiation of Methadone for Refractory Restless Leg Syndrome with Significant Improvement of Symptoms

1180 Restlessness Is a Pain: Methadone Induced Augmentation

0714 Weight Loss in Patients Prescribed Methadone for Restless Legs Syndrome

Opioids for restless legs syndrome

1165 A Challenging Case of Chronic Fentanyl Use Inducing Central Sleep Apnea After Tracheostomy

Severe, childhood-onset, idiopathic, life-long insomnia responding selectively to opiate therapy: case report with 19 year follow-up

Long-term Safety, Dose Stability, and Efficacy of Opioids for Patients With Restless Legs Syndrome in the National RLS Opioid Registry

Pathogenesis of sleep disordered breathing in the setting of opioid use: A multiple mediation analysis using physiology

0986 Inter-Individual Differences in Sleep Architecture of Patients Receiving Methadone for Opioid Use Disorder

0685 Opioid Treatment of Patients with Painful versus Painless Restless Legs Syndrome

1166 Long-term Buprenorphine Use and Prevalence of Sleep Apnea: A Case Series

The effect of acute exposure to morphine on breathing variability and cardiopulmonary coupling in men with obstructive sleep apnea: A randomized controlled trial.

Predictive factors for sleep apnoea in patients on opioids for chronic pain

The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial

0494 Sleep Related Respiratory Events on Buprenorphine Compared to Naltrexone

Opioids for Chronic Refractory Breathlessness: Right Patient, Right Route?

Acute Respiratory Failure Secondary to Low-Dose Opioid Administration in a Patient With Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome After Undergoing Trans-sphenoidal Tumor Resection

The Influence of Acute Morphine Use on Obstructive Sleep Apnea: A Systematic Review and Meta‐analysis

0914 Retrospective Review of Sedative Use on Hospitalized Patients at Risk for OSA

0911 Characterizing Sleep, Pain, and Opioid Craving in People with Chronic Low Back Pain on Long Term Opioid Therapy